報價延遲最少15分鐘:2024/12/25 01:34 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.63 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.76/-0.02
|
|
企業價值
696.86M
|
| 資產負債 |
|
每股賬面淨值
-0.49
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
124.67K
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/25 01:34 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States. |